Chris A. Rallis - 10 Jun 2026 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: Director
Issuer ticker: FENC
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 17:24:49 UTC
Prior SEC filing: 12 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Chris Rallis

Key filing fact

Chris A. Rallis filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 10 Jun 2026.

Key facts

This page summarizes Chris A. Rallis's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 17:24.

Change

Previous filing in this sequence was filed on 12 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001185945 Primary reporting owner

RALLIS CHRIS A

Relationship: Director
Address: C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK
Signature: /s/ Chris Rallis
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Stock Option

Award

Transaction value
Shares: +20,000
Change %: +11%
Price: $8.70^*
Shares after: 200,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 20,000
Exercise price: $8.70
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

Footnote F2

The option is 100% vested on date of grant.